These data imply that the reduction in SIRT1 and SIRT6 mRNA levels could be restored in COPD patients, suggesting administration of these antagomirs as a potential therapy to reverse the accelerated aging phenotype of COPD patients. Here, SIRT6 is linked to chronic obstructive pulmonary disease.